Lotus Pharmaceutical Co (美時化學製藥), which makes and distributes oral and injected medicine, yesterday said its future parent company Alvogen Inc spent US$187 million to acquire South Korean-based Dream Pharma Ltd, which is to be put under Lotus’ control once the deal is approved.
The US-based Alvogen, which makes generic drugs and biosimilars, plans to acquire the company through its South Koran subsidiary Kunwha Pharmaceutical Co, and the deal is still pending approval from the South Korean government, Lotus said.
Alvogen expects the deal to be completed in the fourth quarter of this year. The deal would make Kunwha the largest generic drug maker in South Korea, Lotus said.
The acquisition should strengthen Kunwha’s retail routes in South Korea and increase Kunwha’s product portfolio because the two companies sell different products, and Alvogen is set to sell its products to Taiwan and other markets in Asia using Alvogen’s networks, Lotus said.
“[The Asia-Pacific region] is one of the fastest-growing regions globally for generic pharmaceuticals. The market remains very fragmented, which provides an excellent opportunity for Alvogen to play a leading role in further industry consolidation,” Alvogen said in its statement yesterday.
Dream Pharma, a subsidiary of Hanwha Chemical Corp, which makes polyethylene, polyvinyl chloride plasticizer and base chemicals, reported revenue of about US$100 million last year, with 56 percent of that from sales of weight-loss drugs, Lotus said.
With 100 drugs currently in the pipeline, Dream Pharma accounts for 35 percent of the South Korean weight-loss drug market, according to Lotus.
“Dream Pharma is not a core business for Hanwha, and we believe we can increase its profit by adjusting Dream Pharma’s structure after acquiring it,” Lotus vice president Hung Yao-le (洪堯樂) said by telephone yesterday.
Alvogen is to spend US$200 million to acquire 67 percent of Lotus’ shares on Aug. 12, and Lotus also plans to spend US$180 million to seize 100 percent of South Korea-based Alvogen Korea and other Asian subsidiaries of Alvogen, Lotus said.
After Lotus acquired Alvogen Korea, Lotus would have a 67 percent stake in Kunwha, which posted a revenue of about US$80 million last year, Lotus said.
Both Dream Pharma and Kunwere in the black for last year, Hung said.
WEAKER ACTIVITY: The sharpest deterioration was seen in the electronics and optical components sector, with the production index falling 13.2 points to 44.5 Taiwan’s manufacturing sector last month contracted for a second consecutive month, with the purchasing managers’ index (PMI) slipping to 48, reflecting ongoing caution over trade uncertainties, the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The decline reflects growing caution among companies amid uncertainty surrounding US tariffs, semiconductor duties and automotive import levies, and it is also likely linked to fading front-loading activity, CIER president Lien Hsien-ming (連賢明) said. “Some clients have started shifting orders to Southeast Asian countries where tariff regimes are already clear,” Lien told a news conference. Firms across the supply chain are also lowering stock levels to mitigate
Six Taiwanese companies, including contract chipmaker Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), made the 2025 Fortune Global 500 list of the world’s largest firms by revenue. In a report published by New York-based Fortune magazine on Tuesday, Hon Hai Precision Industry Co (鴻海精密), also known as Foxconn Technology Group (富士康科技集團), ranked highest among Taiwanese firms, placing 28th with revenue of US$213.69 billion. Up 60 spots from last year, TSMC rose to No. 126 with US$90.16 billion in revenue, followed by Quanta Computer Inc (廣達) at 348th, Pegatron Corp (和碩) at 461st, CPC Corp, Taiwan (台灣中油) at 494th and Wistron Corp (緯創) at
NEGOTIATIONS: Semiconductors play an outsized role in Taiwan’s industrial and economic development and are a major driver of the Taiwan-US trade imbalance With US President Donald Trump threatening to impose tariffs on semiconductors, Taiwan is expected to face a significant challenge, as information and communications technology (ICT) products account for more than 70 percent of its exports to the US, Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) president Lien Hsien-ming (連賢明) said on Friday. Compared with other countries, semiconductors play a disproportionately large role in Taiwan’s industrial and economic development, Lien said. As the sixth-largest contributor to the US trade deficit, Taiwan recorded a US$73.9 billion trade surplus with the US last year — up from US$47.8 billion in 2023 — driven by strong
ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip assembly and testing service provider, yesterday said it would boost equipment capital expenditure by up to 16 percent for this year to cope with strong customer demand for artificial intelligence (AI) applications. Aside from AI, a growing demand for semiconductors used in the automotive and industrial sectors is to drive ASE’s capacity next year, the Kaohsiung-based company said. “We do see the disparity between AI and other general sectors, and that pretty much aligns the scenario in the first half of this year,” ASE chief operating officer Tien Wu (吳田玉) told an
RSS